Lupin Ltd

Oxcarbazepine ER tablets, 150 mg, 300 mg, and 600 mg are bioequivalent to Oxtellar XR ER tablets, 150 mg, 300 mg, and 600 mg, of Supernus Pharmaceuticals, Inc., and are indicated for the treatment of partial-onset seizures in patients 6 years of age and older. This product would be manufactured at Lupin's Nagpur facility in India. Oxcarbazepine ER tablets (RLD Oxtellar XR) had estimated annual sales of $206 million in the U.S. (IQVIA MAT April 2025). Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company's consolidated net profit surged 114.9% to Rs 772.52 crore on 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.20% to end at Rs 1,999.20 on the BSE.Powered by Capital Market - Live

Lupin has granted 7,337 stock options on 27 May 2025. Please note that upon vesting, one stock option entitles the grantee to subscribe to one equity share of the Company of Rs 2.00 each. The vesting schedule of stock options will be 25%:25%:25%:25% over four years upon completion of one year from the date of grant.Powered by Capital Market - Live

Lupin has allotted 78,930 equity shares under Stock Option plans of the Company. Accordingly, the issued and paid-up share capital of the Company has increased to Rs 91,33,90,940 consisting of 45,66,95,470 equity shares of Rs 2/- each.Powered by Capital Market - Live

Lupin has entered into a license and supply agreement with SteinCares, a leading specialty healthcare company in Latin America, for commercialization of Lupin's biosimilar ranibizumab across Latin America excluding Mexico and Argentina. Under the terms of the agreement, SteinCares will handle all regulatory filings, registrations and commercialization of Ranibizumab in LATAM, while Lupin will be responsible for manufacturing the same. Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularization (mCNV). Powered by Capital Market - Live

Lupin announced today its plan to use Honeywell's Solstice' Air (HFO-1234ze cGMP) propellant to transform respiratory care through the development of next-generation inhalers. Designed for patients with asthma and chronic obstructive pulmonary disease (COPD), Honeywell Solstice Air has the potential to prevent the release of high global warming potential (GWP) molecules, marking a major step forward in helping to reduce carbon emissions. Lupin intends to become the first pharmaceutical company in India to use Honeywell's Solstice Air product at scale as a next-generation propellant in pressurized metered-dose inhalers (pMDIs). Solstice Air offers an alternative to traditional hydrofluorocarbon (HFC)-based propellants, helping to reduce greenhouse gas emissions by up to 99.9%.1 By investigating the use of this innovative, non flammable propellant in its pMDIs, Lupin is taking a significant step toward minimizing the environmental impact of respiratory solutions while providing effective treatment options for patients with asthma and COPD. LPowered by Capital Market - Live

Lupin announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Rivaroxaban Tablets USP, 10 mg, 15 mg, and 20 mg. Rivaroxaban Tablets are bioequivalent to Xarelto' Tablets, 10 mg, 15 mg, and 20 mg, of Janssen Pharmaceuticals. This product will be manufactured at Lupin's Aurangabad facility in India.Powered by Capital Market - Live

Lupin announced that the Board of Directors of the Company at its meeting held on 14 May 2025, inter alia, have recommended the final dividend of Rs 12 per equity Share (i.e. 600%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Securities in F&O Ban: Central Depository Services (CDSL), Manappuram Finance and Hindustan Copper shares are banned from F&O trading on 15 May 2025. Upcoming Results: Abbott India, Allied Blenders and Distillers, Alivus Life Sciences, Arvind, Balrampur Chini Mills, Bombay Burmah Trading Corporation, Bikaji Foods International, BLS International Services, Caplin Point Laboratories, CESC, Cochin Shipyard, Crompton Greaves Consumer Electricals, Godfrey Phillips, JSW Energy, LIC Housing Finance, P N Gadgil Jewellers, Solara Active Pharma, Welspun Enterprises, Allied Blenders and Distillers, Bikaji Foods International, BLS International will declare their result later today. Stocks to Watch: Lupin's consolidated net profit surged 114.9% to Rs 772.52 crore on 13.6% increase in net sales to Rs 5,562 crore in Q4 FY25 over Q4 FY24. Eicher Motors reported a 27.25% increase in consolidated net profit to Rs 1,362.15 crore in Q4 FY25 as against Rs 1,070.45 crore posted in Q4 FY24. Total revenue from operations rose 23.4% YoY to Rs 5,150.38 crore in the quarter ended 31 March 2025. Tata Power Company's consolidated net profit jumped 16.49% to Rs 1,042.83 crore on a 7.88% increase in revenue from operations to Rs 17,095.88 crore in Q4 FY25 over Q4 FY24. Sagility India's consolidated net profit surged 127.6% to Rs 182.57 crore on a 22.2% jump in net sales to Rs 1,568.48 crore in Q4 FY25 over Q4 FY24. Tilaknagar Industries reported a 145.9% jump in consolidated net profit to Rs 77.35 crore on 13.1% increase in net sales to Rs 405.81 crore in Q4 FY25 over Q4 FY24. Baazar Style Retail's standalone net loss narrowed to Rs 6.39 crore in Q4 FY25 as compared with net loss of Rs 6.43 crore in Q4 FY24. Net sales jumped 54.5% YoY to Rs 345.37 crore in Q4 FY25. Agi Greenpac reported 49.6% jump in standalone net profit to Rs 96.61 crore on a 13.3% increase in net sales to Rs 704.83 crore in Q4 FY25 over Q4 FY24. Le Travenues Technology (Ixigo) reported 85.8% jump in consolidated net profit to Rs 16.72 crore on a 72.4% increase in net sales to Rs 281.14 crore in Q4 FY25 over Q4 FY24. Powered by Capital Market - Live

Net profit of Lupin rose 114.93% to Rs 772.52 crore in the quarter ended March 2025 as against Rs 359.43 crore during the previous quarter ended March 2024. Sales rose 13.63% to Rs 5562.20 crore in the quarter ended March 2025 as against Rs 4895.11 crore during the previous quarter ended March 2024. For the full year,net profit rose 71.41% to Rs 3281.62 crore in the year ended March 2025 as against Rs 1914.48 crore during the previous year ended March 2024. Sales rose 12.90% to Rs 22192.11 crore in the year ended March 2025 as against Rs 19656.34 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales5562.204895.11 14 22192.1119656.34 13 OPM %23.7520.36 -23.8119.39 - PBDT1289.02954.81 35 5184.263619.08 43 PBT895.84497.71 80 4015.002422.27 66 NP772.52359.43 115 3281.621914.48 71 Powered by Capital Market - Live

The tablets are the generic version of Jynarque, developed by Otsuka Pharmaceutical Company, and are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). The product has an estimated annual market size of $1,467 million in the U.S. for the fiscal year ended 31 December 2024. Vinita Gupta, CEO of Lupin, said, 'We are pleased to announce the launch of Tolvaptan Tablets in the U.S. to provide ADPKD patients with increased access to high-quality treatment options.' Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company's consolidated net profit jumped 39.5% to Rs 855.16 crore in Q3 FY25 as compared with Rs 613.12 crore in Q4 FY24. Net sales increased 10.6% YoY to Rs 5618.56 crore during the quarter ended 31st March 2025.Powered by Capital Market - Live